AMENDMENTS TO THE CLAIMS

In the claims, please cancel claims and 19 and amend claims as follows:

- (currently amended) A composition comprising: a T7 ligand <u>covalently</u> attached to a compound, <u>said compound selected from the list consisting of: drug, complex and</u> polynucleotide.
- 2. (canceled)
- (currently amended) The composition of claim [[2]] 1 wherein the drug comprises interferon.
- (canceled)
- (currently amended) The composition of claim [[4]] 1 wherein the complex consists of a liposome.
- (currently amended) The composition of claim [[4]] 1 wherein the complex consists of a polyplex.
- (currently amended) The composition of claim [[4]] \(\frac{1}{2}\) wherein the complex consists of
 a lipopolyplex.
- (currently amended) The composition of claim [[4]] 1 wherein the complex comprises a
 polynucleotide.
- (original) The composition of claim 8 wherein the polynucleotide consists of an expression cassette.
- (original) The composition of claim 8 wherein the polynucleotide consists of an RNA.
- (currently amended) The composition of claim 1 wherein the eompound polynucleotide consists of an RNA function inhibitor.
- 12. (original) The composition of claim 1 wherein the T7 ligand comprises SEQ ID 1.
- (original) The composition of claim 1 wherein the T7 ligand contains a functional group.
- 14. (original) The composition of claim 13 wherein the functional group consists of a thiol.
- 15. (original) The composition of claim 14 wherein the thiol consists of a cysteine.
- 16. (original) The composition of claim 13 wherein the functional group consists of biotin.
- (original) The composition of claim 13 wherein the functional group consists of streptavidin.
- 18. (canceled)
- 19. (canceled)

- (original) The composition of claim 1 wherein the T7 ligand is attached to the compound via a linker.
- (currently amended) The composition of claim 20 wherein the linker consists of a [[PEG]] polyethylene glycol.
- 22. (original) The composition of claim 1 wherein the T7 ligand consists of a T7 phage.
- (original) The composition of claim 1 wherein the T7 ligand consists of a T7 p17 protein.
- (original) The composition of claim 1 wherein the T7 ligand consists of a T7 p17 derived peptide.
- (original) The composition of claim 24 wherein the T7 p17 peptide consists of the T7 p17 rod domain.
- 26. (canceled)
- (original) The composition of claim 1 wherein the T7 ligand consists of: T7 ligandcysteine-PDP-streptavidin.
- (original) The composition of claim 1 wherein the T7 ligand consists of T7 ligand-PEG-biotin.
- (currently amended) A pharmaceutical preparation comprising: a compound selected from the list consisting of: drug, complex and polynucleotide associated with covalently attached to a T7 ligand.
- (currently amended) A composition for targeting hepatocytes in vivo comprising: a T7
 ligand associated with covalently attached to a compound, said compound selected
 from the list consisting of: drug, complex and polynucleotide.